---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125361"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:59:44.049197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M

## Summary
- Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.
- NDA submitted for paltusotine (oral somatostatin agonist) for acromegaly; FDA decision expected Dec 2024.
- Upsized public offering raised $575M gross; pro-forma cash ~$1.4B, funding operations into 2029.
- Four candidates in IND-enabling studies; first NDC platform candidate data at NANETS Nov 2024; TSH antagonist IND expected 2025.
- R&D expenses $61.9M (+41% YoY); G&A $25.9M (+67% YoY), driven by pipeline expansion and launch prep.

## SEC filing metadata
- accession: 0000950170-24-125361
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/0000950170-24-125361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/crnx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125361
- JSON: https://secwatch.observer/filing/0000950170-24-125361.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.